Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors

• Status: Recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this exploratory study is to test whether [18F]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will be used to support further development of [18F]3F-PHPG as a clinical tool for neuroendocrine tumor localization and staging.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Michigan Rogel Cancer Center
• Treatments: 3-Iodobenzylguanidine

Criteria

Inclusion Criteria:

• Current neuroendocrine tumor diagnosis

• Able to lie flat for 60 minutes

• Provision of informed consent

Exclusion Criteria:

• Pregnancy or lactation

• Claustrophobia

• Inability to lie flat for 60 minutes

• Currently taking medications that may alter PET scans of neuroendocrine tumors with these tracers, including any of the following:

• Tricyclic antidepressants, which inhibit the norepinephrine transporter:

desipramine, amitriptyline, imipramine

• Cold medications containing the sympathomimetic amines: phenylephrine, phenylpropanolamine, pseudoephedrine

• Nasal decongestants (some use phenylephrine as the active agent)

• Cocaine (which inhibits the norepinephrine transporter)

• Tetrabenazine (Xenazine), which inhibits the VMAT2 transporter

• Monoamine oxidase inhibitors (MAOI)

• Some antihypertensive drugs: reserpine, labetalol, α-methyldopa, clonidine